Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Fernando Bazan

Radiology
600 N Union Ave, 
New Braunfels, TX 
Accepting New Patients
Experienced in WT1-Related Wilms Tumor Syndromes
600 N Union Ave, 
New Braunfels, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Fernando Bazan is a Radiologist in New Braunfels, Texas. Dr. Bazan is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pleural Effusion, Rhizarthrosis, Breast Lump, and CAPOS Syndrome. Dr. Bazan is currently accepting new patients.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in TX
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

600 N Union Ave, New Braunfels, TX 78130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Not Applicable
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Enrollment Status: Completed
Publish Date: January 27, 2025
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
Enrollment Status: Terminated
Publish Date: December 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: August 21, 2024
Intervention Type: Device
Study Phase: Not Applicable
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
Enrollment Status: Completed
Publish Date: March 07, 2024
Intervention Type: Drug
Study Drugs: MCLA-128, Trastuzumab, Vinorelbine, Endocrine Therapy
Study Phase: Phase 2
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Enrollment Status: Unknown
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: AZD2014, Anastrozole
Study Phase: Phase 1/Phase 2
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Enrollment Status: Unknown
Publish Date: December 07, 2023
Intervention Type: Biological
Observational Retrospective Cohort Study in Patients With Relapsed Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated With Olaparib Following Response to Platinium-based Chemotherapy
Observational Retrospective Cohort Study in Patients With Relapsed Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated With Olaparib Following Response to Platinium-based Chemotherapy
Enrollment Status: Completed
Publish Date: September 06, 2023
Intervention Type: Drug
Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer
Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Device, Behavioral
Study Phase: Not Applicable
View 10 Less Clinical Trials

44 Total Publications

Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
Journal: JNCI cancer spectrum
Published: July 14, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ariel Y. Kruger
Radiology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ariel Y. Kruger
Radiology

South Texas Radiology Group PA

7700 Floyd Curl Dr, 
San Antonio, TX 
 (30.5 miles away)
210-575-4343
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ariel Kruger is a Radiologist in San Antonio, Texas. Dr. Kruger is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Diverticular Disease, Lung Nodules, Progressive Familial Intrahepatic Cholestasis Type 2, and Gastrostomy. Dr. Kruger is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Pablo I. Pallan
Radiology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Pablo I. Pallan
Radiology

South Texas Radiology Group PA

1310 Mccullough Ave, 
San Antonio, TX 
 (29.1 miles away)
210-757-2284
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pablo Pallan is a Radiologist in San Antonio, Texas. Dr. Pallan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Ascites, Visceromegaly, Non-Alcoholic Fatty Liver Disease, Bone Marrow Aspiration, and Liver Embolization. Dr. Pallan is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Simon Trubek
Radiology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Simon Trubek
Radiology

Singleton Associates PA

12221 N Mopac Expy, 
Austin, TX 
 (54.2 miles away)
713-461-3573
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Simon Trubek is a Radiologist in Austin, Texas. Dr. Trubek is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Nodules, Gastric Lymphoma, Neuroendocrine Tumor, and WT1-Related Wilms Tumor Syndromes. Dr. Trubek is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bazan's expertise for a condition
ConditionClose
      View All 20 Advanced Conditions
      View All 66 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile